drugset
drugset / Trial / NCT02269202

Pharmacokinetics of Midazolam, With and Without Concomitant Administration of Crobenetine in Healthy Male Subjects

NCT02269202 ↗

Phase 1 Completed 20 enrolled Boehringer Ingelheim
RandomizedSingle-blindTreatment

Summary

To assess the pharmacokinetics of midazolam with/without concomitant administration of crobenetine

Timeline

Start
2002-02
Primary completion
2002-04
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject Crobenetine Small molecule 175 mg Intravenous
Subject Midazolam Small molecule 7.5 mg Oral

Indications

No indication recorded.